Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

3.29
-0.0600-1.79%
Post-market: 3.28-0.0100-0.30%17:28 EDT
Volume:2.54M
Turnover:8.36M
Market Cap:638.26M
PE:-4.33
High:3.35
Open:3.32
Low:3.25
Close:3.35
52wk High:6.44
52wk Low:2.56
Shares:194.00M
Float Shares:164.00M
Volume Ratio:0.59
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7600
EPS(LYR):-0.9999
ROE:-28.87%
ROA:-17.20%
PB:1.35
PE(LYR):-3.29

Loading ...

ALT Resources Sets Date and Venue for 2026 Annual General Meeting

TIPRANKS
·
May 06

CCL Industries closes ALT Technologies acquisition

TIPRANKS
·
May 01

Altimmune closes USD 225 million follow-on stock offering with warrants

Reuters
·
Apr 27

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

THOMSON REUTERS
·
Apr 27

Altimmune Inc: Financing Funds Operations Through Anticipated Phase 3 Mash 52-Week Data Readout

THOMSON REUTERS
·
Apr 27

Altimmune Inc: Intends to Use Net Proceeds to Fund Its Upcoming Phase 3 Trial in Mash, Expects to Initiate Its Phase 3 Trial in Mash in H2

THOMSON REUTERS
·
Apr 27

Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

prnewswire
·
Apr 26

Altimmune upgraded to Neutral from Sell at Goldman Sachs

TIPRANKS
·
Apr 24

BUZZ-U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks

Reuters
·
Apr 24

Altimmune Shares Drop After $225 Million Offering Prices

Dow Jones
·
Apr 23

ALT Resources Advances Tartana Reverse Takeover and Secures £208,750 Funding

TIPRANKS
·
Apr 23

Altimmune prices oversubscribed USD 225 million public offering with warrants

Reuters
·
Apr 23

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

THOMSON REUTERS
·
Apr 23

BRIEF-Altimmune Announces Proposed Underwritten Public Offering Of Securities

Reuters
·
Apr 23

Altimmune launches underwritten public offering with common stock, warrants

Reuters
·
Apr 23

Altimmune Announces Proposed Underwritten Public Offering of Securities

THOMSON REUTERS
·
Apr 23

Altimmune Inc - Net Proceeds to Fund Phase 3 Mash Trial and General Purposes

THOMSON REUTERS
·
Apr 23

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire
·
Apr 22

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma

GlobeNewswire
·
Apr 20

Altimmune shareholders approved increase in authorized common shares to 400 million

Reuters
·
Apr 17